Technical Analysis for DERM - Dermira, Inc.
|Grade||Last Price||% Change||Price Change|
DERM closed down 4.15 percent on Friday, November 16, 2018, on 1.25 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical DERM trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 16||Slingshot Bearish||Bearish Swing Setup||0.00%|
|Nov 16||Spinning Top||Other||0.00%|
|Nov 16||Lower Bollinger Band Walk||Weakness||0.00%|
|Nov 16||Multiple of Ten Bearish||Other||0.00%|
|Nov 16||Outside Day||Range Expansion||0.00%|
|Nov 16||Wide Bands||Range Expansion||0.00%|
|Nov 16||Lower Bollinger Band Touch||Weakness||0.00%|
|Nov 16||Oversold Stochastic||Weakness||0.00%|
|Nov 15||Stochastic Buy Signal||Bullish||-4.15%|
|Nov 15||Lower Bollinger Band Walk||Weakness||-4.15%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more DERM news...
|52 Week High||31.42|
|52 Week Low||6.98|
|200-Day Moving Average||11.6391|
|50-Day Moving Average||11.4456|
|20-Day Moving Average||11.598|
|10-Day Moving Average||10.927|
|Average True Range||0.9036|
|Chandelier Exit (Long, 3 ATRs )||11.1292|
|Chandelier Exit (Short, 3 ATRs )||11.9208|
|Upper Bollinger Band||13.6725|
|Lower Bollinger Band||9.5235|
|Percent B (%b)||0.04|
|MACD Signal Line||-0.1388|
|Market Cap||405.53 Million|
|Num Shares||41.8 Million|
|Price-to-Earnings (P/E) Ratio||-3.60|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||11.68|
|Resistance 3 (R3)||11.73||11.12||11.35|
|Resistance 2 (R2)||11.12||10.62||11.10||11.24|
|Resistance 1 (R1)||10.42||10.31||10.12||10.37||11.13|
|Support 1 (S1)||9.11||9.31||8.81||9.06||8.29|
|Support 2 (S2)||8.50||9.00||8.48||8.18|
|Support 3 (S3)||7.80||8.50||8.07|
|Support 4 (S4)||7.75|